Disability and Therapeutic Response in Paediatric Neuromyelitis Optica Spectrum Disorder

A Case Series from Iran

Seyed Mohammad Baghbanian, Mohammad Ali Sahraian, Abdorreza Naser Moghadasi, Nasrin Asgari

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Objectives: The characteristics of paediatric neuromyelitis optica spectrum disorder (NMOSD) may indicate the degree of disability and identify factors that predict the response to treatment.

Materials & Methods: Among 114 NMOSD patients in an acquired demyelinating syndromes registry at the Sina Hospital, in Tehran, Iran, 10 paediatric NMOSD patients with longitudinal follow-up from 2005 to 2016 were retrospectively identified. The median time between disease onset and diagnosis was 18 months (range 1-108 months).

Results: All patients had a relapsing course, which resulted in disability in six with severe visual impairment and functional blindness in one and impaired ambulation in five patients during follow-up. Azathioprine (AZA) was first drug of choice for prophylaxis, but in five patients new attacks occurred and therapy was switched to rituximab (RTX) with no further relapses after median two years (range 1-3 y) follow-up.

Conclusion: Paediatric onset of NMOSD was associated with severe attacks and poor response in 50 % of cases to AZA, RTX seemed to decrease the relapse rate.

Original languageEnglish
JournalIranian journal of child neurology
Volume13
Issue number3
Pages (from-to)99-104
ISSN2008-0700
DOIs
Publication statusPublished - 2019

Fingerprint

Neuromyelitis Optica
Iran
Pediatrics
Registries
Pharmaceutical Preparations

Keywords

  • Disability
  • Neuromyelitis optica spectrum disorder
  • Paediatric
  • Treatment

Cite this

Baghbanian, Seyed Mohammad ; Sahraian, Mohammad Ali ; Naser Moghadasi, Abdorreza ; Asgari, Nasrin. / Disability and Therapeutic Response in Paediatric Neuromyelitis Optica Spectrum Disorder : A Case Series from Iran. In: Iranian journal of child neurology. 2019 ; Vol. 13, No. 3. pp. 99-104.
@article{77fb54f9815243709d288841100cd620,
title = "Disability and Therapeutic Response in Paediatric Neuromyelitis Optica Spectrum Disorder: A Case Series from Iran",
abstract = "Objectives: The characteristics of paediatric neuromyelitis optica spectrum disorder (NMOSD) may indicate the degree of disability and identify factors that predict the response to treatment.Materials & Methods: Among 114 NMOSD patients in an acquired demyelinating syndromes registry at the Sina Hospital, in Tehran, Iran, 10 paediatric NMOSD patients with longitudinal follow-up from 2005 to 2016 were retrospectively identified. The median time between disease onset and diagnosis was 18 months (range 1-108 months).Results: All patients had a relapsing course, which resulted in disability in six with severe visual impairment and functional blindness in one and impaired ambulation in five patients during follow-up. Azathioprine (AZA) was first drug of choice for prophylaxis, but in five patients new attacks occurred and therapy was switched to rituximab (RTX) with no further relapses after median two years (range 1-3 y) follow-up.Conclusion: Paediatric onset of NMOSD was associated with severe attacks and poor response in 50 {\%} of cases to AZA, RTX seemed to decrease the relapse rate.",
keywords = "Disability, Neuromyelitis optica spectrum disorder, Paediatric, Treatment",
author = "Baghbanian, {Seyed Mohammad} and Sahraian, {Mohammad Ali} and {Naser Moghadasi}, Abdorreza and Nasrin Asgari",
year = "2019",
doi = "10.22037/ijcn.v13i3.22715",
language = "English",
volume = "13",
pages = "99--104",
journal = "Iranian journal of child neurology",
issn = "2008-0700",
number = "3",

}

Disability and Therapeutic Response in Paediatric Neuromyelitis Optica Spectrum Disorder : A Case Series from Iran. / Baghbanian, Seyed Mohammad; Sahraian, Mohammad Ali; Naser Moghadasi, Abdorreza; Asgari, Nasrin.

In: Iranian journal of child neurology, Vol. 13, No. 3, 2019, p. 99-104.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Disability and Therapeutic Response in Paediatric Neuromyelitis Optica Spectrum Disorder

T2 - A Case Series from Iran

AU - Baghbanian, Seyed Mohammad

AU - Sahraian, Mohammad Ali

AU - Naser Moghadasi, Abdorreza

AU - Asgari, Nasrin

PY - 2019

Y1 - 2019

N2 - Objectives: The characteristics of paediatric neuromyelitis optica spectrum disorder (NMOSD) may indicate the degree of disability and identify factors that predict the response to treatment.Materials & Methods: Among 114 NMOSD patients in an acquired demyelinating syndromes registry at the Sina Hospital, in Tehran, Iran, 10 paediatric NMOSD patients with longitudinal follow-up from 2005 to 2016 were retrospectively identified. The median time between disease onset and diagnosis was 18 months (range 1-108 months).Results: All patients had a relapsing course, which resulted in disability in six with severe visual impairment and functional blindness in one and impaired ambulation in five patients during follow-up. Azathioprine (AZA) was first drug of choice for prophylaxis, but in five patients new attacks occurred and therapy was switched to rituximab (RTX) with no further relapses after median two years (range 1-3 y) follow-up.Conclusion: Paediatric onset of NMOSD was associated with severe attacks and poor response in 50 % of cases to AZA, RTX seemed to decrease the relapse rate.

AB - Objectives: The characteristics of paediatric neuromyelitis optica spectrum disorder (NMOSD) may indicate the degree of disability and identify factors that predict the response to treatment.Materials & Methods: Among 114 NMOSD patients in an acquired demyelinating syndromes registry at the Sina Hospital, in Tehran, Iran, 10 paediatric NMOSD patients with longitudinal follow-up from 2005 to 2016 were retrospectively identified. The median time between disease onset and diagnosis was 18 months (range 1-108 months).Results: All patients had a relapsing course, which resulted in disability in six with severe visual impairment and functional blindness in one and impaired ambulation in five patients during follow-up. Azathioprine (AZA) was first drug of choice for prophylaxis, but in five patients new attacks occurred and therapy was switched to rituximab (RTX) with no further relapses after median two years (range 1-3 y) follow-up.Conclusion: Paediatric onset of NMOSD was associated with severe attacks and poor response in 50 % of cases to AZA, RTX seemed to decrease the relapse rate.

KW - Disability

KW - Neuromyelitis optica spectrum disorder

KW - Paediatric

KW - Treatment

U2 - 10.22037/ijcn.v13i3.22715

DO - 10.22037/ijcn.v13i3.22715

M3 - Journal article

VL - 13

SP - 99

EP - 104

JO - Iranian journal of child neurology

JF - Iranian journal of child neurology

SN - 2008-0700

IS - 3

ER -